Presentation is loading. Please wait.

Presentation is loading. Please wait.

A New Schedule of CHOP/Rituximab Plus Granulocyte-Macrophage Colony-Stimulating Factor Is an Effective Rescue for Patients with Aggressive Lymphoma Failing.

Published byVivien McBride Modified over 5 years ago

Similar presentations

Presentation on theme: "A New Schedule of CHOP/Rituximab Plus Granulocyte-Macrophage Colony-Stimulating Factor Is an Effective Rescue for Patients with Aggressive Lymphoma Failing."— Presentation transcript:

1 A New Schedule of CHOP/Rituximab Plus Granulocyte-Macrophage Colony-Stimulating Factor Is an Effective Rescue for Patients with Aggressive Lymphoma Failing Autologous Stem Cell Transplantation  Attilio Olivieri, Moira Lucesole, Debora Capelli, Guido Gini, Mauro Montanari, Marco Candela, Emanuela Troiani, Ilaria Scortechini, Antonella Poloni, Pietro Leoni  Biology of Blood and Marrow Transplantation  Volume 11, Issue 8, Pages (August 2005) DOI: /j.bbmt Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Schedule of treatment in 20 patients with aggressive lymphoma and failed ASCT. Doxo indicates doxorubicin; CTX, cyclophosphamide; VCR, vincristine; ANC, absolute neutrophil count; sm, square meter; MPDN, prednisone. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Effects of GM-CSF administration for 10 days in a woman with leukemic MCL; CD20+ cells increased from 80% to 95%, and median-intensity fluorescence (MIF) increased from 120 to 216. The QuantiCALC assay allowed enumeration of the CD20 density per single cell, which increased from to in the high density cluster (upper), from 7083 to in the intermediate density cluster (medium), and from 755 to 455 in the low density cluster (down) respectively, in the lymphoma cells. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 First restaging after 2 courses of CHOP/rituximab/GM-CSF, 2 weeks after the fourth RTX infusion. AlloTx indicates allogeneic transplantation; uCR, CR unconfirmed. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 OS in 20 patients with aggressive NHL. CI indicates confidence interval. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

6 Figure 5 PFS in 20 patients with aggressive NHL. CI indicates confidence interval. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

7 Figure 6 OS in 14 DLCL patients. CI indicates confidence interval.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

8 Figure 7 PFS in 14 DLCL patients. CI indicates confidence interval.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

9 Figure 8 Computed tomographic scan of a young woman after a DLCL relapse 6 months after ASCT, with mediastinal bulky disease involving the lung and pleural effusion (A) after 4 courses of CHOP/GM-CSF/RTX (B). The same patient (C and D) showed extensive liver and renal involvement at relapse. E and F, Complete regression of lymphoma. The patient is in CCR 4 years after the end of therapy. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "A New Schedule of CHOP/Rituximab Plus Granulocyte-Macrophage Colony-Stimulating Factor Is an Effective Rescue for Patients with Aggressive Lymphoma Failing."

Similar presentations

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation  Sarah J. Kizilbash, Clifford E. Kashtan,

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation  Sarah J. Kizilbash, Clifford E. Kashtan,
Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed.

Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed.
Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach  Robert Frank Cornell, Parameswaran.

Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach  Robert Frank Cornell, Parameswaran.
Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates  Ian Nivison-Smith, Judy M. Simpson, Anthony.

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates  Ian Nivison-Smith, Judy M. Simpson, Anthony.
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin’s Lymphoma (HL) in the ABVD Therapeutic Era  Sarah F. Keller,

Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin’s Lymphoma (HL) in the ABVD Therapeutic Era  Sarah F. Keller,
Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin.

Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin.
Vaccination of Children following Allogeneic Stem Cell Transplantation

Vaccination of Children following Allogeneic Stem Cell Transplantation
Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.
Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI  Alix O’Meara, Jörg Halter, Dominik.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI  Alix O’Meara, Jörg Halter, Dominik.
Primary CNS Lymphoma—Radiation-Free Salvage Therapy by Second Autologous Stem Cell Transplantation  Benjamin Kasenda, M.D., Elisabeth Schorb, M.D., Kristina.

Primary CNS Lymphoma—Radiation-Free Salvage Therapy by Second Autologous Stem Cell Transplantation  Benjamin Kasenda, M.D., Elisabeth Schorb, M.D., Kristina.
Immune Reconstitution after Autologous Hematopoietic Cell Transplant (AHCT) in B-Cell Non-Hodgkin Lymphoma (B-NHL) Patients Mobilized with Granulocyte.

Immune Reconstitution after Autologous Hematopoietic Cell Transplant (AHCT) in B-Cell Non-Hodgkin Lymphoma (B-NHL) Patients Mobilized with Granulocyte.
Allogeneic Stem Cell Transplantation in Myelofibrosis

Allogeneic Stem Cell Transplantation in Myelofibrosis
Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,
A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular.

A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular.
Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.
Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis  Danielle H. Oh, Haocheng.

Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis  Danielle H. Oh, Haocheng.
Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma  Navneet S. Majhail, Daniel J. Weisdorf,

Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma  Navneet S. Majhail, Daniel J. Weisdorf,
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Basal CD34+ Cell Count Predicts Peripheral Blood Stem Cell Mobilization in Healthy Donors after Administration of Granulocyte Colony–Stimulating Factor:

Basal CD34+ Cell Count Predicts Peripheral Blood Stem Cell Mobilization in Healthy Donors after Administration of Granulocyte Colony–Stimulating Factor:

Similar presentations

Ads by Google